The security of supply of critical medicines and the strengthening of EU's pharmaceutical sector have been key priorities for the EU in the last few months. The recent EPSCO Council discussions underscore the urgent need to strengthen the European Health Union in light of the Draghi Report on the future of European competitiveness. However, critical challenges threaten the EU’s pharmaceutical resilience. Insufficient R&D, slow regulatory processes, and reliance on non-EU suppliers for active pharmaceutical ingredients (APIs) expose significant vulnerabilities. To address these, the EU must act decisively, aligning strategies through initiatives like the Critical Medicines Act and the Pharmaceutical Package to reduce dependency, bolster local production, and secure equitable access to medicines.
Dive into this month’s LUHNIP Monthly Brief for EU Industrial Policy to uncover:
- How could consolidation in the telecommunications sector enhance the EU's global competitiveness, and why is it creating divisions among Member States?
- How is the EU's Critical Medicines Act aimed at addressing supply chain vulnerabilities and reducing dependency on non-EU pharmaceutical suppliers?
- How EU industrial policy can be better aligned with the objectives of environmental transition and cohesion of the single market (a guest contribution by Dario Guarascio, Jelena Reljic, and Annamaria Simonazzi from the Sapienza Università di Roma )?
The LUHNIP Monthly Brief on EU Industrial Policy is your quick 10-minute read on the top 10 must-know developments in EU industrial policy, plus in-depth analyses of key events.
👉🏻 Read the brief here: https://lnkd.in/gbZPUYCv
🔹 Visit the LUHNIP Website: https://lnkd.in/e7fbErxK
🔹 Join our WhatsApp channel for updates: https://lnkd.in/eJZF_izb
🔹 Subscribe to the LEAP Newsletter: https://lnkd.in/eZgwBfC3
#LUHNIP #GreenIndustrialPolicy #DigitalInfrastructure #TelecomsReform #CriticalMedicines
Dimitri Zurstrassen Marco Simoni
Commercial Business Development @ AVALON Pharma |
2mo👏🏻 👏🏻👏🏻